当前位置： SCI文献检索 > VACCINE期刊下所有文献 > Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus.

Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus.

Abstract：

:The Middle East respiratory syndrome coronavirus (MERS-CoV) is a highly pathogenic and zoonotic virus with a fatality rate in humans of over 35%. Although several vaccine candidates have been developed, there is still no clinically available vaccine for MERS-CoV. In this study, we developed two types of MERS-CoV vaccines: a recombinant adenovirus serotype 5 encoding the MERS-CoV spike gene (Ad5/MERS) and spike protein nanoparticles formulated with aluminum (alum) adjuvant. Next, we tested a heterologous prime-boost vaccine strategy, which compared priming with Ad5/MERS and boosting with spike protein nanoparticles and vice versa, with homologous prime-boost vaccination comprising priming and boosting with either spike protein nanoparticles or Ad5/MERS. Although both types of vaccine could induce specific immunoglobulin G against MERS-CoV, neutralizing antibodies against MERS-CoV were induced only by heterologous prime-boost immunization and homologous immunization with spike protein nanoparticles. Interestingly, Th1 cell activation was induced by immunization schedules including Ad5/MERS, but not by those including only spike protein nanoparticles. Heterologous prime-boost vaccination regimens including Ad5/MERS elicited simultaneous Th1 and Th2 responses, but homologous prime-boost regimens did not. Thus, heterologous prime-boost may induce longer-lasting immune responses against MERS-CoV because of an appropriate balance of Th1/Th2 responses. However, both heterologous prime-boost and homologous spike protein nanoparticles vaccinations could provide protection from MERS-CoV challenge in mice. Our results demonstrate that heterologous immunization by priming with Ad5/MERS and boosting with spike protein nanoparticles could be an efficient prophylactic strategy against MERS-CoV infection.

journal_name

Vaccine

journal_title

Vaccine

authors

Jung SY,Kang KW,Lee EY,Seo DW,Kim HL,Kim H,Kwon T,Park HL,Kim H,Lee SM,Nam JH

doi

10.1016/j.vaccine.2018.04.082

subject

Has Abstract

pub_date

2018-06-07 00:00:00

pages

3468-3476

issue

24

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(18)30598-X

journal_volume

36

pub_type

杂志文章

相关文献

VACCINE文献大全
  • Role of different genes in the CS6 operon for surface expression of Enterotoxigenic Escherichia coli colonization factor CS6.

    abstract：:Coli surface antigen 6, CS6, is one of the most prevalent colonization factors (CFs) associated with Enterotoxigenic Escherichia coli (ETEC) bacteria, the most common cause of diarrhea among infants and children in developing countries. The CS6 operon encodes two structural subunit proteins, CssA and CssB, a chaperon,...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2008.07.091

    authors： Tobias J,Lebens M,Källgård S,Nicklasson M,Svennerholm AM

    更新日期：2008-10-03 00:00:00

  • Estimating the economic impact of pneumococcal conjugate, Haemophilus influenzae type b and rotavirus vaccines in India: National and state-level analyses.

    abstract：BACKGROUND:To support vaccine decision-making we estimated from the societal perspective the potential health impact and costs averted through immunization with three vaccines - Haemophilus influenzae type b (Hib), pneumococcal conjugate vaccine (PCV) and rotavirus vaccine (RVV). METHODS:Based on variability in diseas...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2019.09.084

    authors： Constenla D,Liu T

    更新日期：2019-12-10 00:00:00

  • Feasibility of using regional sentinel surveillance to monitor the rotavirus vaccine impact, effectiveness and intussusception incidence in the African Region.

    abstract：:The 9th African rotavirus symposium was held in Maputo, Mozambique from the 8th to 10th of December 2015, including a total of 101 delegates from 17 countries, 15 of which were African countries. This forum brought together participants with various expertise including scientists, clinicians, immunization program mana...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2017.01.072

    authors： Mandomando I,Weldegebriel G,de Deus N,Mwenda JM

    更新日期：2017-03-23 00:00:00

  • Factors influencing influenza vaccination uptake in an elderly, community-based sample.

    abstract：:This study investigated predictors of influenza vaccination uptake since the introduction of the policy to target over 65s. Four hundred and forty-four participants completed a cross-sectional structured interview. The predictors of vaccination uptake were: having a doctor or nurse who explained why the vaccination is...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2004.12.031

    authors： Burns VE,Ring C,Carroll D

    更新日期：2005-05-20 00:00:00

  • Conformational restriction of peptidyl immunogens with covalent replacements for the hydrogen bond.

    abstract：:A new strategy for designing synthetic vaccines is presented. In this approach synthetic peptides are conformationally restricted by replacing putative hydrogen bonds with covalent mimics. The chemistry for substituting a hydrazone-ethane link (N-N = CH-CH2-CH2) for an (i + 4)----i hydrogen bond in a pentapeptide with...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/s0264-410x(88)80007-0

    authors： Satterthwait AC,Arrhenius T,Hagopian RA,Zavala F,Nussenzweig V,Lerner RA

    更新日期：1988-04-01 00:00:00

  • A novel DNA adjuvant, N3, enhances mucosal and systemic immune responses induced by HIV-1 DNA and peptide immunizations.

    abstract：AIMS:The study was designed to evaluate a novel cationic lipid DNA adjuvant (N3) and its function for HIV-1gp160/rev DNA plasmid delivered intranasally. The primary N3/HIV-DNA plasmid immunizations were boosted intranasally with a gp41 peptide in a anionic L3 adjuvant. This novel prime-boost strategy of mucosal immuniz...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2005.08.015

    authors： Hinkula J,Devito C,Zuber B,Benthin R,Ferreira D,Wahren B,Schröder U

    更新日期：2006-05-22 00:00:00

  • A novel mouse model for immunogenic evaluation of human HBV vaccines.

    abstract：:To prepare a human HBV vaccine, investigators need an animal model that can help them screen and prioritize vaccine candidates. In this study, HBV/HLA-A2.1 double transgenic mice (dTg), confirmed by analysis of genomic integration and by observation of long-term expression of HBV and HLA genes, were generated for the ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2009.06.088

    authors： Guo Y,Ren D,He X,Wang F,Jiang L,Song S,He Y,Sun S

    更新日期：2009-09-18 00:00:00

  • Induction of a cellular immune response to a defined T-cell epitope as an insert in the flagellin of a live vaccine strain of Salmonella.

    abstract：:Attenuated strains of Salmonella have been used as vaccines to deliver heterologous antigens mainly to generate a humoral immune response. However, little is known about their ability to induce a cell-mediated immune response to the T-cell epitopes of another infectious agent or how optimally to deliver these epitopes...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/0264-410x(95)93308-v

    authors： Verma NK,Ziegler HK,Stocker BA,Schoolnik GK

    更新日期：1995-02-01 00:00:00

  • Generation of an immune microenvironment as a novel mechanism for myotoxins to potentiate genetic vaccines.

    abstract：:We recently reported that administration of low doses of myotoxins at vaccination sites potentiated antigen-specific T-cell immunity induced by genetic cancer vaccines in mice, an effect which was superior to TLR agonists. In the current study, we found unexpectedly that the mechanism of this potent adjuvant effect wa...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2010.09.084

    authors： Qin H,Cha SC,Neelapu SS,Liu C,Wang YH,Wei J,Qin XF,Liu YJ,Kwak LW

    更新日期：2010-11-23 00:00:00

  • Parents' preferences for seasonal influenza vaccine for their children in Japan.

    abstract：:In Japan, trivalent inactivated influenza vaccine is the only approved influenza vaccine. It is typically administrated by hypodermic injection, and children under 13 years of age are recommended to be vaccinated two times during each winter season. Live-attenuated influenza vaccine (LAIV) is administered by a thimero...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2014.07.002

    authors： Shono A,Kondo M

    更新日期：2014-09-03 00:00:00

  • Homotopes affect primary and secondary antibody responses in poultry.

    abstract：:Activation of the innate immune system by different homotopes may direct the subsequent specific immune response, and as a consequence may have significant implications on vaccination. In this study, effects of i.v. administered lipopolysaccharide (LPS), and lipoteichoic acid (LTA), respectively, and s.c. administered...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2004.11.037

    authors： Maldonado LM,Lammers A,Nieuwland MG,De Vries Reilingh G,Parmentier HK

    更新日期：2005-04-15 00:00:00

  • Development of an in vitro-based potency assay for anthrax vaccine.

    abstract：:The potency assay currently used to evaluate consistency of manufacture for the anthrax vaccine is contingent upon meeting specified parameters after statistical analysis of the percent survival and time to death of vaccinated guinea pigs after challenge with spores of a virulent strain of Bacillus anthracis. During t...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2003.12.027

    authors： Little SF,Webster WM,Ivins BE,Fellows PF,Norris SL,Andrews GP

    更新日期：2004-07-29 00:00:00

  • Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine.

    abstract：:TA-CIN is a vaccine that comprises the human papillomavirus (HPV) type 16 L2, E6 and E7 as a single fusion protein. In a mouse model, TA-CIN effectively prevented outgrowth of HPV16-positive tumour cells. To assess the safety and immunogenicity of TA-CIN, a dose escalating (26, 128, 533 micro g), double blind and plac...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1016/s0264-410x(02)00350-x

    authors： de Jong A,O'Neill T,Khan AY,Kwappenberg KM,Chisholm SE,Whittle NR,Dobson JA,Jack LC,St Clair Roberts JA,Offringa R,van der Burg SH,Hickling JK

    更新日期：2002-10-04 00:00:00

  • Impact of quadrivalent HPV vaccine dose spacing on immunologic response in women living with HIV.

    abstract：:HPV vaccination schedules have changed as evidence has supported reduced dosing and extended intervals. Women living with HIV (WLWH) represent an important population with no data on alternative dosing. Girls and WLWH received quadrivalent HPV (qHPV) vaccine in a pan-Canadian study of immunogenicity and efficacy. Sero...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2020.02.075

    authors： McClymont E,Ogilvie G,Albert A,Johnston A,Raboud J,Walmsley S,Lipsky N,Loutfy M,Trottier S,Smaill F,Yudin MH,Klein MB,Harris M,Wobeser W,Bitnun A,Kakkar F,Samson L,Brophy J,Karatzios C,Money D,CTN 236 HPV in HIV S

    更新日期：2020-03-30 00:00:00

  • Age-related trends in the timeliness and prediction of medical visits, hospitalizations and deaths due to pneumonia and influenza, British Columbia, Canada, 1998-2004.

    abstract：:The influenza immunization program in North America has been primarily designed to provide direct benefit to vaccinated individuals at highest risk of serious influenza outcomes. Some evidence suggests that immunization of certain age groups may also extend indirect protective benefit to vulnerable populations. Our go...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2007.11.090

    authors： Sebastian R,Skowronski DM,Chong M,Dhaliwal J,Brownstein JS

    更新日期：2008-03-04 00:00:00

  • Immune response to a booster dose of enhanced potency inactivated polio vaccine administered in association with HBV vaccine in adolescents.

    abstract：:The immunogenicity and reactogenicity of a booster dose of enhanced potency inactivated polio vaccine (EIPV) were evaluated in 492 healthy 12 year old adolescents. The booster was administered at the same time as the HBV vaccine compulsory in Italy at this age. Blood samples and questionnaires on reactogenicity were c...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章

    doi：10.1016/0264-410x(95)00209-j

    authors： Pregliasco F,Grilli G,Andreassi A,D'Addezio E,Vacca F,Squarcione S,Biasio LR,Profeta M

    更新日期：1996-03-01 00:00:00

  • Human papillomavirus infection among human immunodeficiency virus-infected women in Maharashtra, India.

    abstract：INTRODUCTION:Frequency and distribution of HPV types in HIV-infected women with and without cervical neoplasia and their determinants have not been widely studied in India. We report and discuss HPV prevalence and type distribution in HIV-infected women. METHODS:HPV genotyping was done using cervical samples from 1109...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2013.12.060

    authors： Joshi S,Babu JM,Jayalakshmi D,Kulkarni V,Divate U,Muwonge R,Gheit T,Tommasino M,Sankaranarayanan R,Pillai MR

    更新日期：2014-02-19 00:00:00

  • Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection.

    abstract：:Clinical trials with pandemic influenza vaccine candidates have focused on aluminium hydroxide as an adjuvant to boost humoral immune responses. In this study we investigated the effect of aluminium hydroxide on the magnitude and type of immune response induced by whole-inactivated virus (WIV) vaccine. Balb/c mice wer...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2008.02.063

    authors： Bungener L,Geeraedts F,Ter Veer W,Medema J,Wilschut J,Huckriede A

    更新日期：2008-05-02 00:00:00

  • Polio Eradication Initiative: Contribution to improved communicable diseases surveillance in WHO African region.

    abstract：INTRODUCTION:Since the launch of the Global Polio Eradication Initiative (GPEI) in 1988, there has been a tremendous progress in the reduction of cases of poliomyelitis. The world is on the verge of achieving global polio eradication and in May 2013, the 66th World Health Assembly endorsed the Polio Eradication and End...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2016.05.060

    authors： Mwengee W,Okeibunor J,Poy A,Shaba K,Mbulu Kinuani L,Minkoulou E,Yahaya A,Gaturuku P,Landoh DE,Nsubuga P,Salla M,Mihigo R,Mkanda P

    更新日期：2016-10-10 00:00:00

  • Efficacy study of a new albumin-free human diploid cell rabies vaccine (Lyssavac-HDC, Berna) in 100 severely rabies-exposed Thai patients.

    abstract：:A newly developed human diploid cell rabies vaccine (Lyssavac-HDC), produced without added serum albumin and with an effort to remove the virus-inactivating beta-propriolactone prior to addition of the gelatin, L-cysteine and potassium phosphate stabilizer, was tested for safety immunogenicity, adverse reactions and e...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章

    doi：10.1016/0264-410x(94)00049-s

    authors： Wilde H,Glueck R,Khawplod P,Cryz SJ,Tantawichien T,Thipkong P,Chomchey P,Prakongsri S,Benjavongkulchai M,Sumboonanondha A

    更新日期：1995-04-01 00:00:00

  • Murine helper T lymphocyte response to influenza virus: recognition of haemagglutinin by subtype-specific and cross-reactive T cell clones.

    abstract：:Helper T cel lines specific for influenza virus were established by continuous culture of Mem 71-Bel (H3) virus-immune spleen cells in the presence of virus and antigen-presenting cells and their specificity assessed in proliferation experiments. A line stimulated in vitro with Mem 71-Bel virus was able to proliferate...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/0264-410x(85)90118-5

    authors： Katz JM,Brown LE,Ffrench RA,White DO

    更新日期：1985-09-01 00:00:00

  • Adverse events following immunization in patients with primary immunodeficiencies.

    abstract：BACKGROUND:Adverse events following immunization (AEFI) requires special consideration in patients with primary immunodeficiency diseases (PID) because they may represent a "red flag" for the initial diagnosis and may cause disease complications. Therefore, the definition of appropriate vaccination schemes is a major i...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2016.01.047

    authors： Sarmiento JD,Villada F,Orrego JC,Franco JL,Trujillo-Vargas CM

    更新日期：2016-03-18 00:00:00

  • Colinear synthesis of an antigen-specific B-cell epitope with a 'promiscuous' tetanus toxin T-cell epitope: a synthetic peptide immunocontraceptive.

    abstract：:Carrier conjugation is commonly used to provide T-cell help for small, linear peptides containing antigen-specific B-cell epitopes. However, carrier conjugation is expensive, variable and often results in adverse side effects if the conjugate is administered repeatedly. To eliminate the need for carrier conjugation, w...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(97)00105-9

    authors： O'Hern PA,Liang ZG,Bambra CS,Goldberg E

    更新日期：1997-11-01 00:00:00

  • Economics of polio vaccination in the post-eradication era: should OPV-using countries adopt IPV?

    abstract：:The continued use of oral polio vaccine (OPV) poses a threat to polio virus eradication. Stopping all polio vaccination in the post-certification era is no longer considered to be a practical option. Policy makers agree that OPV use must stop immediately after certification. Therefore, the pragmatic alternative is for...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2008.02.008

    authors： Khan MM

    更新日期：2008-04-07 00:00:00

  • Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study.

    abstract：BACKGROUND:Shigellae cause severe disease in endemic countries, especially in children. Several efficacy trials have been conducted with candidate vaccines against Shigellae, but the lack of protection, the safety concerns, or manufacturing challenges hindered successful market approval. Conjugated vaccines have been s...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2015.06.102

    authors： Hatz CF,Bally B,Rohrer S,Steffen R,Kramme S,Siegrist CA,Wacker M,Alaimo C,Fonck VG

    更新日期：2015-08-26 00:00:00

  • Vaccinia virus proteins activate human dendritic cells to induce T cell responses in vitro.

    abstract：:The mechanisms of protection elicited by smallpox vaccine in humans have not been delineated. Dendritic cells (DCs) are the most potent of professional antigen presenting cells which on activation modulate both innate and adaptive immune responses. Immunogenic proteins of vaccinia virus have been identified with prote...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2008.10.031

    authors： Agrawal S,Gupta S,Agrawal A

    更新日期：2009-01-01 00:00:00

  • Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.

    abstract：:In a phase I/II dose escalation study, varying volumes (0.1 ml, 0.5 ml, 1.0 ml and 2.0 ml) of 7-valent pneumococcal conjugate vaccine (PCV) (Prevnar or 0.5 ml of 23-valent pneumococcal polysaccharide vaccine (PPV) were administered to 220 adults 70 through 79 years of age previously vaccinated with 0.5 ml PPV at age 6...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章

    doi：10.1016/j.vaccine.2005.02.017

    authors： Jackson LA,Neuzil KM,Whitney CG,Starkovich P,Dunstan M,Yu O,Nelson JC,Feikin DR,Shay DK,Baggs J,Carste B,Nahm MH,Carlone G

    更新日期：2005-05-25 00:00:00

  • Heat shock protein complex vaccination induces protection against Helicobacter pylori without exogenous adjuvant.

    abstract：BACKGROUND:The development of a vaccine against the human gastric pathogen Helicobacter pylori, the main causative agent of gastric adenocarcinoma, has been hampered by a number of issues, including the lack of a mucosal adjuvant for use in humans. Heat shock proteins (Hsp), highly conserved molecules expressed by both...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2014.02.051

    authors： Chionh YT,Arulmuruganar A,Venditti E,Ng GZ,Han JX,Entwisle C,Ang CS,Colaco CA,McNulty S,Sutton P

    更新日期：2014-04-25 00:00:00

  • US Military contributions to the global response to pandemic chikungunya.

    abstract：:Chikungunya virus, transmitted by mosquitoes to man, causes an acute illness characterized by fever, rash and striking joint symptoms. US Military investigators developed, manufactured at The Salk Institute-Government Services Division (TSI-GSD), and tested the live, attenuated Chikungunya Vaccine TSI-GSD-218. The man...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2012.08.025

    authors： Hoke CH Jr,Pace-Templeton J,Pittman P,Malinoski FJ,Gibbs P,Ulderich T,Mathers M,Fogtman B,Glass P,Vaughn DW

    更新日期：2012-10-19 00:00:00

  • Early disappearance of maternal anti-measles, mumps, rubella, and varicella antibodies in Indian infants.

    abstract：BACKGROUND:Immunization of children with vaccines against Measles, Mumps, Rubella, and Varicella (MMRV) is practiced globally with varied recommendations. In India, measles vaccine is administered alone or as MMR at 9 months age. Varicella vaccine is not routinely used. Immunization age is a function of disappearance o...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2019.01.043

    authors： Malshe N,Palkar S,Kulkarni R,Lalwani S,Mishra AC,Arankalle V

    更新日期：2019-03-07 00:00:00